Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Globo-H-GM2-Lewis-y-MUC1-32(aa)-sTn(c)-TF(c)-Tn(c)-KLH conjugate vaccine
- Development stage
- Phase 1
- Lead developer
- Memorial Sloan Kettering Cancer Center
- Modality
- Vaccines & Immunotherapeutics, Peptides
- Administration
- Subcutaneous, Intramuscular
01
Overview
The Globo-H-GM2-Lewis-y-MUC1-32(aa)-sTn(c)-TF(c)-Tn(c)-KLH conjugate vaccine is a polyvalent cancer vaccine developed by Memorial Sloan Kettering Cancer Center (MSKCC). It is designed to target seven tumor-associated carbohydrate antigens (TACAs) that are frequently overexpressed on the surface of epithelial cancer cells: Globo-H, GM2, Lewis Y, MUC1, sialyl-Tn (sTn), Thomsen-Friedenreich (TF), and Tn. Each of these antigens is individually conjugated to the immunogenic carrier protein Keyhole Limpet Hemocyanin (KLH). The vaccine is typically co-administered with the saponin-based adjuvant QS-21 to enhance the immune response, primarily inducing IgM and sometimes IgG antibodies against the targeted antigens. It has been investigated in pilot clinical trials for patients with high-risk breast cancer and ovarian, fallopian tube, or peritoneal cancers in remission to prevent recurrence by targeting micrometastatic disease.
- Other names
- Globo-H-GM2-Lewis-y-MUC1-32(aa)-sTn(c)-TF(c)-Tn(c)-KLH conjugate vaccineHeptavalent antigen-keyhole limpet hemocyanin conjugate vaccineHeptavalent-KLH conjugate vaccineMSKCC heptavalent vaccineHeptavalent carbohydrate-protein conjugate vaccine
02
Targets
Globo-HLeY (Lewis Y antigen)STn-MUC1 (Sialyl-Tn-MUC1)TF antigen (Thomsen-Friedenreich antigen)Tn (Tn antigen)GM2 (Ganglioside GM2)
Beyond the preview
Go deeper on Globo-H-GM2-Lewis-y-MUC1-32(aa)-sTn(c)-TF(c)-Tn(c)-KLH conjugate vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Globo-H-GM2-Lewis-y-MUC1-32(aa)-sTn(c)-TF(c)-Tn(c)-KLH conjugate vaccine.